Pfizer's Litfulo Hits Endpoints in Nonsegmental Vitiligo Studies
Complete. Here is the key summaryPfizer announced that its oral drug Litfulo met key endpoints in two Phase 3 studies for nonsegmental vitiligo. Both 50mg and 100mg doses showed significant repigmentation improvement versus placebo at 52 weeks. Based on these results, Pfizer plans to submit global regulatory filings for Litfulo as a systemic therapy for adults with the condition. Litfulo was previously approved by the FDA in 2023 for severe alopecia areata.
By Colin Kellaher
Pfizer said a pair of late-stage studies of its Litfulo oral hair-loss drug met their key goals in the chronic depigmenting disorder nonsegmental vitiligo.
Pfizer on Thursday said the Phase 3 studies of Litfulo met their co-primary endpoints, with both the 50- and 100-milligram once-daily doses showing significant improvement in facial and total repigmentation versus placebo at 52 weeks in patients with both active and stable nonsegmental vitiligo who had a broad range of disease severity.
The New York drugmaker said that, based on the study results, it plans to submit global regulatory filings for Litfulo as a potential new oral systemic therapy for adults with nonsegmental vitiligo.
The U.S. Food and Drug Administration in 2023 approved Litfulo for the treatment of severe alopecia areata in people ages 12 and older.
Pfizer said it plans to launch a pivotal study evaluating Litfulo for the treatment of moderate alopecia areata this year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 30, 2026 08:03 ET (12:03 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.